STAG2 and idiopathic pulmonary fibrosis: Lung-targeted PCAR-MSCs demonstrated improved therapeutic efficacy in the treatment of IPF, highlighting the potential of the SA2-PEG-peptide strategy for broader applications in cell modification and disease therapy.